SecBot SecBot
SECBOTREPLAY Home › Report › IMNM

IMNM · Barclays initiated coverage on Immunome Inc

Immunome Inc. · ANALYST-UPGRADE filed

At the news

BULLISHIMPACT 3/10

ANALYST-UPGRADE filed

Barclays initiated coverage on Immunome Inc. (IMNM) at Overweight with a $36 price target, implying 66% upside from the current $21.66. The call aligns with an overwhelmingly bullish consensus, 95% of 20 analysts rate the stock Buy or Strong Buy, with only one Hold. The mean price target of $35.23 is nearly identical to Barclays' $36, placing the firm in line with the Street. Barclays carries a 54% accuracy rate on 6,762 calls with a +3.9% average return, a solid but not elite track record. EPS revisions have been strongly positive over the past 30 days, 9 upward revisions vs. 1 downward, signaling improving fundamentals. Insider activity shows a notable buy from director Clay B. Siegall ($500K) on March 27 and a $103K buy from Jean Jacques Bienaime on May 15, both bullish signals that converge with the analyst upgrade. Institutional buying is also heavy, with FMR LLC adding 26.8% and Bank of America doubling its position. The bottom line: Barclays' initiation is a consensus-aligned call from a mid-tier firm, but strong insider buying and institutional accumulation add conviction to the bullish thesis.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access